How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/infection-caused-by-carbapenem-resistant-acinetobacter-baumannii-calcoaceticus-complex.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Infection caused by carbapenem-resistant acinetobacter baumannii-calcoaceticus complex — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Infection caused by carbapenem-resistant acinetobacter baumannii-calcoaceticus complex (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Infection caused by carbapenem-resistant acinetobacter baumannii-calcoaceticus complex, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Xacduro (Copackaged)	DURLOBACTAM	Entasis Therap	beta Lactamase Inhibitor			2023-01-01
Unasyn	SULBACTAM	Pfizer	beta Lactamase Inhibitor	Serine beta-lactamase-like protein LACTB, mitochondrial		1986-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Entasis Therap · 1 drug in Infection caused by carbapenem-resistant acinetobacter baumannii-calcoaceticus complex
Pfizer · 1 drug in Infection caused by carbapenem-resistant acinetobacter baumannii-calcoaceticus complex

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Infection caused by carbapenem-resistant acinetobacter baumannii-calcoaceticus complex:

Cite this brief

Drug Landscape (2026). Infection caused by carbapenem-resistant acinetobacter baumannii-calcoaceticus complex — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/infection-caused-by-carbapenem-resistant-acinetobacter-baumannii-calcoaceticus-complex. Accessed 2026-06-10.

Infection caused by carbapenem-resistant acinetobacter baumannii-calcoaceticus complex full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing